CARD: Overall survival (OS) analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide.
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Bertrand F. Tombal, Daniel Castellano, Gero Kramer, Jean-Christophe Eymard, Johann S. De Bono, Cora N. Sternberg, Karim Fizazi, Christian Wulfing, Aristotelis Bamias, Joan Carles, Roberto Iacovelli, Bohuslav Melichar, Asgerdur Sverrisdottir, Christine Theodore, Susan Feyerabend, Carole Helissey, Elizabeth Poole, Ayse Ozatilgan, Christine Geffriaud-Ricouard, Ronald De Wit
Institutions: UCLouvain, Hospital Universitario 12 De Octubre, University of Vienna, Institut Jean Godinot, Institute of Cancer Research, Royal Marsden Hospital, Weill Cornell Medicine, Université Paris-Sud, Institut Gustave Roussy, Asklepios Klinik Altona, Asklepios, National and Kapodistrian University of Athens, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Azienda Ospedaliera Universitaria Integrata Verona, University Hospital Olomouc, National University Hospital of Iceland, Hôpital Foch, Sanofi (France), Erasmus MC
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Sanofi
OpenAlex ID: W3030762477